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Group B Streptococcus (GBS; Streptococcus agalactiae) is a major cause of illness and death in young in-
fants worldwide (1–3). A recent systematic review re-
ported the global incidence to be 0.49 cases/1,000 live 
births (4). It is estimated that this incidence results in 
≈90,000 deaths (uncertainty death range 36,000–169,000) 
in infants every year (5). Furthermore, ≈32% of infants 
who survive GBS meningitis have neurodevelopmental 
impairment 18 months after illness, including 18% who 
have moderate-to-severe neurodevelopmental impair-
ment (6). GBS is also a major cause of preterm delivery, 
stillbirths, and puerperal sepsis (5,7).
Screening pregnant women for GBS and offering 
intrapartum antimicrobial drug prophylaxis (IAP) 
to those who are found to be colonized, or have risk 
factors, has been widely implemented in many coun-
tries (8). However, the increased use of antimicrobial 
drugs has raised concerns regarding the emergence of 
resistance (9). Clindamycin and erythromycin resis-
tance rates have increased greatly in the past 20 years 
(10) but might vary by geographic location (10,11). 
Knowledge of local antimicrobial drug resistance of 
GBS strains can contribute to optimal prophylactic 
and treatment strategies.
On the basis of the polysaccharide capsule, GBS 
strains are classified into 10 serotypes (12). A global 
review showed that serotype III was the most frequent 
isolate from infants who had invasive disease (4). Se-
rotyping is of particular relevance to GBS vaccine de-
velopment because most current candidates include 
serotype-specific polysaccharide–protein conjugate 
vaccines (13). An effective vaccine will need to pre-
vent most infant disease, avoid the limitations of IAP, 
and cost-effective. Therefore, knowledge of prevalent 
serotypes will be relevant to country-specific deci-
sions for vaccine implementation.
Evidence regarding the burden of invasive GBS 
disease in infants in China is limited. The recent 
systematic review found only 5 studies from China 
and estimated an incidence of 0.42 cases/1,000 live 
births for eastern Asia (4). This review was limited 
because it did not include publications in Mandarin 
Chinese and might not provide an accurate estimate 
of the burden of GBS disease in China. Therefore, we 
performed a systematic review and meta-analysis on 
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We performed a systematic review and meta-analysis of 
the incidence, case-fatality rate (CFR), isolate antimicro-
bial resistance patterns, and serotype and sequence type 
distributions for invasive group B Streptococcus (GBS) dis-
ease in infants <1–89 days of age in China. We searched 
the PubMed/Medline, Embase, Wanfang, and China Na-
tional Knowledge Infrastructure databases for research 
published during January 1, 2000–March 16, 2018, and 
identified 64 studies. Quality of included studies was as-
sessed by using Cochrane tools. Incidence and CFR were 
estimated by using random-effects meta-analyses. Overall 
incidence was 0.55 (95% CI 0.35–0.74) cases/1,000 live 
births, and the CFR was 5% (95% CI 3%–6%). Incidence 
of GBS in young infants in China was higher than the esti-
mated global incidence (0.49 cases/1,000 live births) and 
higher than previous estimates for Asia (0.3 cases/1,000 
live births). Our findings suggest that implementation of 
additional GBS prevention efforts in China, including ma-
ternal vaccination, could be beneficial.
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the incidence, case-fatality rate (CFR), isolate antimi-
crobial resistance (AMR) patterns, and serotype and 
sequence type distributions for invasive GBS disease 
cases in infants <1–89 days of age in China.
Methods
This systematic review was reported according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses guidelines (14). We focused on infants 
<1–89 days of age who had invasive GBS disease. We 
included studies that reported incidence and deaths 
associated with invasive disease, and antimicrobial 
drug resistance, serotypes, and multilocus sequence 
typing (MLST) of GBS isolates. Eligible studies were 
those published during January 1, 2000–March 16, 
2018. The geographic scope of analysis was limited to 
China and included Taiwan, Hong Kong, and Macau.
Definitions
Invasive GBS disease was defined as a positive GBS 
culture from any normally sterile site accompanied 
with signs of clinical disease. Early onset of GBS (EO-
GBS) was defined as isolation of GBS from infants 
<1–6 days after birth, and late onset of GBS (LOGBS) 
was defined as isolation of GBS from infants 7–89 
days after birth. Incidence was defined as cases/1,000 
live births (invasive GBS disease cases divided by live 
births at the respective hospital). CFR was defined as 
number of fatal GBS cases divided by total number 
of GBS cases. We categorized studies as prospective 
(data collected for the infant at admission and in hos-
pital) and retrospective (data collected after the infant 
was discharged from a hospital).
In mainland China, hospitals were classified as 
primary, secondary, or tertiary institutions. A primary 
hospital is typically a township hospital that has <100 
beds. These hospitals are tasked with providing pre-
ventive care, minimal healthcare, and rehabilitation 
services. Secondary hospitals tend to be affiliated with 
a medium-size city, county, or district and have >100 
but <500 beds. These hospitals are responsible for pro-
viding comprehensive health services, as well as med-
ical education and conducting research on a regional 
basis. Tertiary hospitals are comprehensive or general 
hospitals at the city, provincial, or national level that 
have >500 beds. These hospitals provide specialist 
health services, perform a larger role with regard to 
medical education and scientific research, and serve 
as medical hubs providing care to multiple regions.
Search Strategy and Selection Criteria
We searched the PubMed/Medline, Embase, China 
National Knowledge Infrastructure, and Wanfang 
med online databases for literature published dur-
ing January 1, 2000–March 16, 2018. We used the 
search terms “Streptococcus Group B” or “Group B 
streptococcal” OR “Streptococcus agalactiae” (medi-
cal subject headings) AND “infant,” “outcome,” 
“death,” “mortality,” “case AND fatality AND rate” 
for English databases. We used search terms “Group 
B streptococcal” OR “Streptococcus agalactiae” OR 
“GBS” AND “infant” OR “neonatal” in Chinese for 
Chinese databases. We limited searches to China, 
including Taiwan, Hong Kong, and Macau. An ad-
ditional search for serotype data used the search 
terms “Streptococcus Group B serotype” or “Group 
B streptococcal serotype” OR “Streptococcus agalac-
tiae serotype” (medical subject headings) and was 
performed with the same limits as listed above. We 
provide the full search strategy (Appendix Tables 1, 
2, https://wwwnc.cdc.gov/EID/article/26/11/18-
1414-App1.pdf).
We used snowball searches of article reference 
lists, including reviews, to identify additional studies. 
Two independent reviewers (Y.D. and Y.H.) critically 
appraised each paper and discussed discrepancies 
with a third coauthor (P.H.). We screened titles and 
abstracts according to specified inclusion and exclu-
sion criteria, and then selected the full texts, followed 
by the details as described below.
Inclusion and Exclusion Criteria
We included studies with original data on GBS inva-
sive disease in infants <1–89 days of age, which had a 
population denominator (as the total number of live 
births at the respective hospital), CFR, serotype, or 
AMR. We provide full details of inclusion and exclu-
sion criteria (Appendix Table 3).
Data Abstraction and Quality Assessment
Isolates obtained from all normally sterile sites (blood, 
cerebrospinal fluid [CSF], lung aspirate, and joint 
specimens) were included for incidence estimates. 
For AMR, serotype, and MLST data, only isolates 
obtained from blood or CSF cultures were included. 
The quality of included studies was assessed in ac-
cordance with the Cochrane Handbook (15), includ-
ing 9 items considered essential for good reporting of 
prevalence studies. Two independent reviewers (Y.D. 
and Y.H.) critically appraised each study. Disagree-
ments were resolved by discussion with the third re-
viewer (P.H.).
Statistical Analysis
We performed a meta-analysis by using Stata soft-
ware version 14.0 (StataCorp, https://www.stata.
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com) We estimated overall incidence, EOGBS, LOG-
BS incidence, and CFR of GBS with random-effects 
meta-analyses by using the DerSimonian and Laird 
method. The Q test was performed to test heteroge-
neity between studies, and the I2 was used to assess 
the degree of variation across studies. The level of 
heterogeneity was defined as low (I2 = 25%), moder-
ate (I2 = 50%), and high (I2 = 75%) (15). When het-
erogeneity was high, we also performed subgroup 
analysis based on study design (retrospective and 
prospective), isolate type (blood, CSF, and all ster-
ile sites), and age of onset (EOGBS and LOGBS). 
Sensitivity analysis was conduct by excluding stud-
ies from Taiwan, Hong Kong, and Macau. As we 
anticipated, different infectious disease patterns, 
antimicrobial drug resistance, and healthcare sys-
tems in these regions might affect the estimates of 
GBS incidence and CFR. Potential publication bias 
was assessed by using a funnel plot and the Egger 
regression test. Descriptive analysis was performed 
to investigate the distribution of serotype and MLST 
typing. Antimicrobial drug resistance rates were re-
ported by median with interquartile intervals.
Results
Literature Search and Study Selection
We identified 704 published studies from database 
searches (407 from China National Knowledge Infra-
structure, 139 from Wanfang, 147 from PubMed, and 
9 from Embase). Two additional articles were iden-
tified from reference lists. A total of 64 articles met 
our inclusion criteria and search strategy (Figure 1). 
A total of 14 articles reported incidence, 56 articles 
reported CFR, 20 articles reported AMR, 4 articles 
reported serotype, and 2 articles reported MLST. 
We provide a full list of articles included (Appendix 
Table 4) and of articles excluded (Appendix Table 5). 
We provide the publication years of included stud-
ies (Appendix Figure 1).
Study Characteristics
Of the 64 studies included, 55 were from mainland 
China, 7 from Taiwan, 1 from Hong Kong, and 1 from 
Macau. On the basis of economic divisions, 92.2% 
(59/64) of studies were from eastern China, 2 each 
were from western and central China, and 1 was 
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Figure 1. Process of study 
selection of systematic review 
and meta-analyses of incidence 
of group B Streptococcus disease 
in infants and antimicrobial 
resistance, China. CNKI, China 
National Knowledge Infrastructure.
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from northeastern China. Among the 55 articles from 
mainland China, 45 were from tertiary hospitals, 9 
from secondary hospitals, and 1 from a primary hos-
pital. The 7 articles from Taiwan and the 1 article from 
Hong Kong were all from teaching hospitals, and the 
1 article from Macau was from a general hospital. We 
provide the distribution of studies of invasive GBS 
disease reported in China by province (Figure 2).
Among the 14 studies reporting incidence, 13 
were from eastern China, and 1 from western Chi-
na. Six (42.9%) of 14 papers reported use of IAP, all 
from eastern China; 3 (50%) of 6 IAPs were based 
on screening. Of the 56 studies that reported CFRs, 
52 articles were from eastern China and 2 each were 
from central and western China. A total of 20 stud-
ies reported AMR, 19 papers from eastern China and 
1 from northeastern China. Serotypes were available 
from 4 studies, all of them from eastern China. Only 
2 articles included data on MLST. We provide charac-
teristics of included studies and outcome types (Table 
1). We also provide the risk for bias of the studies 
(Appendix Figure 2).
Incidence of Invasive GBS Disease
Of the 14 relevant studies, 13 reported raw data on 
live births, which enabled a meta-analysis to be per-
formed. Of 424,463 live births, 244 infants had inva-
sive GBS disease at the age of 0–89 days; the pooled 
estimated incidence was 0.55 cases/1,000 live births 
(95% CI 0.35–0.74 case/1,000 live births). Significant 
heterogeneity was observed (p = 0.0001, I2 = 85.4%) 
(Figure 3). Subgroup analyses were conducted to 
2654 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 26, No. 11, November 2020
Figure 2. Distribution of study locations in systematic review and meta-analyses of incidence of invasive group B Streptococcus 
disease, by province, China.
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assess heterogeneity by study design, isolate site, and 
age of onset. Among the 13 studies reporting raw data 
on live births, 11 studies distinguished early-onset 
and late-onset cases (n = 3 studies) born in a hospital. 
There were 133 cases of EOGBS for 352,574 live births, 
an incidence of 0.38 cases/1,000 live births (95% CI 
0.25–0.51 cases/1,000 live births), and 33 cases of 
LOGBS for 168,849 live births, an incidence of 0.18 
cases/1,000 live births (95% CI 0.11–0.25 cases/1,000 
live births).We provide results of meta-analysis for 
LOGBS incidence (Appendix Figure 3), for EOGBA 
incidence (Appendix Figure 4), and for subgroup 
analyses (Appendix Table 6).
Sensitivity analysis was conducted to confirm 
the stability and liability of the meta-analysis by 
excluding data for Taiwan, Hong Kong, and Ma-
cau. This exclusion resulted in a pooled incidence 
of invasive GBS disease of 0.44 cases/1,000 live 
births (95% CI 0.25–0.63 cases/1,000 live births) for 
mainland China (Appendix Figure 5). According to 
the funnel plot and p value of the Eggers regression 
test (p = 0.069 [>0.05]), there was no visually appar-
ent publication bias of included studies (Appendix 
Figure 6).
CFRs for GBS Invasive Disease
A total of 56 papers reported CFR data for infants 
<1–89 days of age. Of 1,439 infants with GBS invasive 
disease, 106 died. The overall pooled estimated CFR 
rate was 5.0% (95% CI 3.0%–6.0%). The EOGBS CFR 
was 6.0% (4.0%–8.0%), and LOGBS CFR was 4.0% 
(1.0%–6.0%). We provide results of meta-analysis for 
overall, EOGBS, and LOGBS CFRs (Appendix Fig-
ures 7, 8, and 9, respectively). Sensitivity analysis was 
conducted to confirm the stability and liability of the 
meta-analysis by including only studies from main-
land China. The pooled estimated CFR was 4.0% (95% 
CI 2%.0%–6.0%) when data for only mainland China 
were included (Appendix Figure 5).
Antimicrobial Resistance
A total of 20 articles reported antimicrobial resistance 
for 598 GBS isolates. The highest prevalence of resis-
tance was reported for tetracycline (median 98.0%, 
interquartile range [IQR] 80.0%–100%), followed by 
clindamycin (73.3%m IQR 62.6%–78.7%), erythromy-
cin (64.4%, IQR 56.6%–75%), and ciprofloxacin (25.0%, 
IQR 9.1%–35.2%). There was no reported resistance 
to penicillin, ampicillin, vancomycin, or linezolid. For 
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Table 1. Characteristics of included studies and outcome types for systematic review and meta-analyses of incidence of group B 
Streptococcus disease in infants, China* 
Characteristic 
Type and no. studies 
Total, 64 Incidence, 14 CFR, 56 AMR, 20 Serotypes, 4 MLST, 2 
China       
 Eastern 59 13 52 19 4 2 
 Central 2 0 2 0 0 0 
 Western 2 1 2 0 0 0 
 Northeastern 1 0 0 1 0 0 
Hospital type       
 Mainland China       
  Tertiary 45 6 39 18 4 2 
  Secondary 9 3 9 2 0 0 
  Primary 1 0 1 0 0 0 
 Nonmainland China      0 
  Teaching 8 4 7 0 0 0 
  General 1 1 0 0 0 0 
Study design       
 Prospective 4 3 3 0 1 1 
 Retrospective 60 11 53 20 3 1 
Reporting period, days       
 Full, 0–89 53 11 46 16 4 2 
 Full EOGBS <1–6 7 3 6 2 0 0 
 Full LOGBS 7–89 4 0 4 2 0 0 
Specimen type       
 Blood only 25 5 18 8 2 0 
 CSF only 6 0 6 3 0 0 
 Blood and CSF 23 6 22 9 2 2 
 All sterile sites 4 3 3 0 0 0 
 Blood and CSF plus sputum or gastric fluid 6 0 7 0 0 0 
IAP       
 Any 10 6 9 3 1 1 
 None 4 0 3 2 0 0 
 Unknown 50 8 44 15 3 1 
*AMR, antimicrobial resistance; CFR, case-fatality rate; CSF, cerebrospinal fluid; EOGBS, early onset group B Streptococcus; IAP, intrapartum 
antimicrobial drug prophylaxis; MLST, multilocus sequence typing; LOGBS, late onset group B Streptococcus. 
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ceftriaxone, the median prevalence of resistance was 
0% (IQR 0%–60.0%), although 1 study reported 100% 
prevalence of resistance (1/1 isolates), and 1 study re-
ported 80% resistance (12/15 isolates) (Table 2).
Serotype Distribution
Four studies included data on serotypes for 175 in-
vasive GBS cases. All of these studies were from 
eastern China. Four serotypes (Ia, Ib, III, and V) ac-
counted for 97% of invasive isolates. Serotype III was 
the most common (65%, 114/175), followed by Ib 
(16%, 27/175), Ia (10%, 18/175), and V (6%, 11/175). 
Two articles distinguished EO and LOGBS serotypes; 
there were 24 EOGBS isolates and 52 LOGBS isolates. 
Serotype III predominated in both EO (15/24, 63%) 
and LOGBS (40/52, 77%) (Appendix Figure 10).
MLST
Only 2 studies reported MLST. Of 76 isolates 15 se-
quence types (STs) were reported. A total of 89% 
(68/76) of strains belonged to 6 STs (ST17, ST12, ST23, 
ST1, ST19, and ST650). More than half (58%, 44/74) of 
the samples were ST17, followed by ST12 (9%, 7/76) 
and ST23 (7%, 5/76); ST1, ST19, and ST650 each ac-
counted for 5% (4/76).
Relationship between Serotype and MLST
Only 2/76 papers included data on serotype and 
MLST. A total of 80% (44/55) of serotype III strains 
were shown to be ST17, and 54% (7/13) of serotype Ib 
strains were ST12 (Appendix Table 7).
Discussion
The annual number of births in China ranged from 
15.7 million to 17.8 million between 2001 and 2016 
(16). Thus, with an estimated pooled incidence of 0.55 
cases/1,000 live births (95% CI 0.35–0.74 cases/1,000 
live births), there is a substantial burden of inva-
sive GBS disease for infants in China. This incidence 
is also higher than that for all infants in the recent 
global review (0.49 cases/1,000 live births, 95% CI 
0.43–0.56 cases/1,000 live births) and higher than that 
previously defined for eastern Asia (0.42 cases/1,000 
live births) (4). Unlike most industrialized countries, 
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Figure 3. Overall incidence risk per 1,000 live births of invasive GBS disease in 13 infants <1–89 days of age, China. Vertical dashed 
line indicates a visual assessment of heterogeneity of the studies. If the vertical line can be drawn, forest plots indicate that all studies 
are similar enough to be included for meta-analysis. Error bars indicate 95% CIs. Reference details are provided in the Appendix (https://
wwwnc.cdc.gov/EID/26/11/18-1414-App1.pdf). ES, effect size; GBS, group B Streptococcus disease. 
Group B Streptococcus Disease in Infants, China
there are no national guidelines for GBS screening 
and prevention in China, although in 43% of studies 
from China, IAP was mentioned. However, there are 
no data on the extent to which IAP is currently used 
in China. Previous studies suggest that the low inci-
dence of GBS infection for infants in Asia might be re-
lated to a lower rate of GBS colonization in pregnant 
women (17). A review of colonization identified 30 
studies from China, which included 44,716 women, 
and showed an overall colonization rate of 11.3%. 
However, several studies from China reported much 
higher rates of GBS colonization (31%–36%) (18,19), 
suggesting substantial variability.
The CFR in our study (5.0%, 95% CI, 3.0%–6.0%) 
was lower than that estimated from the global re-
view (8.4%, 95% CI 6.6%–10.2%) (4). Most of our 
data were for level-3 teaching hospitals in which 
use of antimicrobial drugs and standard of medi-
cal care might be higher, which might explain a 
lower mortality rate. We do not have information 
on birthweight and gestational age of infants with 
GBS disease with which we can compare with other 
settings; the CFR for preterm infants is known to be 
much higher (1).
The prevalence of resistance to clindamycin and 
erythromycin appear to be high in China. A study 
in Canada showed the prevalence of resistance to 
clindamycin was 4.5% and to erythromycin was 8% 
(9). In England and Wales, erythromycin resistance 
in isolates causing disease in infants was 15% for 
EO disease and 13% for LO disease (20). In South 
Korea, the prevalence of resistance to erythromycin 
was 42.9%–51.8% and for clindamycin was 55.4% 
(11,21), suggesting that the prevalence might be 
much higher in Asia. This finding is consistent with 
a global systematic review (22) of GBS isolates caus-
ing colonization that reported a pooled prevalence 
of resistance of 25% for erythromycin and 27% for 
clindamycin, and notably higher prevalences in 
Asia (46% for erythromycin and 47% for clindamy-
cin). A study of colonization of pregnant women in 
China also reported that most isolates were resistant 
to tetracycline (76.9%), erythromycin (72.1%) and 
clindamycin (66.4%) (23). Macrolide resistance in 
streptococci is caused mainly by a macrolide–spe-
cific efflux mechanism encoded by the mef A gene 
and ribosomal modification by a methylase associ-
ated with erm (erythromycin ribosome methylase) 
genes (24,25). Erythromycin resistance was associ-
ated mainly with ermB and mef (A/E) genes in China 
(26,27). The erm(B) and erm(TR/A) genes were the 
main macrolide-resistant genes in Spain and Canada 
(9,25), and erm B and lnuB genes were prevalent in 
South Korea (28).
Resistance to erythromycin and clindamycin pres-
ents a challenge for treatment and prophylaxis strate-
gies because these antimicrobial drugs are often used 
for patients in China who are allergic to penicillin. 
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Table 2. Proportion of isolates demonstrating antimicrobial resistance in systematic review and meta-analyses of incidence of group B 





isolates PEN AMP CFZ CAX VAN LZD CHL ERY TET CIP MXF LVX NIT TGC 
Zeng et al. 2013 11 0 0 NT NT 0 0 NT NT 100.0 9.1 9.1 9.1 0 0 
Luo et al. 2013 15 0 0 NT 0 0 NT NT 86.7 NT NT NT 0 NT NT 
Zheng et al. 2014 12 0 0 NT NT 0 NT NT 16.7 66.7 NT NT NT NT NT 
Chen et al. 2014 16 0 0 NT 0 0 NT NT 62.5 NT 25.0 NT 18.8 NT NT 
Zhu et al. 2014 13 0 10.0 0 100.0 38.5 0 100.0 100.0 NT 33.3 NT 8.3 0 NT 
Fan et al. 2014 42 0 0 NT NT 0 0 NT 69.1 73.8 NT NT 38.1 NT 0 
Wang et al. 2015 15 0 20.0 40.0 80.0 0 0 86.7 100.0 NT 26.7 NT 20.0 0 NT 
Zhang et al. 2015 6 0 0 83.3 NT 0 0 NT NT NT NT NT NT NT NT 
Lei et al. 2015 20 NT 0 NT NT 0 0 25.0 75.0 NT 80.0 NT 70.0 0 NT 
Zhang et al. 2015 45 0 2.2 NT NT 0 0 NT 42.2 93.3 0 0 0 NT 0 
Cai et al. 2016 15 0 0 NT NT 0 0 NT 46.7 100.0 NT 6.7 6.7 13.3 0 
Zhao  2016 28 0 0 NT 0 0 3.6 NT 67.9 NT NT NT 42.9 NT NT 
Huang et al. 2016 49 NT NT NT NT NT NT NT 63.3 98.0 11.9 12.2 7.7 NT NT 
Liu et al. 2017 15 0 NT NT NT 0 NT NT NT NT NT NT NT NT NT 
Zhang et al. 2017 55 0 0 NT NT 0 0 NT 56.6 98.1 1.9 NT NT NT NT 
Zhang et al. 2017 15 6.7 0 NT NT 0 0 NT NT 80.0 73.3 73.3 60.0 0 0 
Tan et al. 2017 20 0 0 NT NT 0 0 NT NT 100.0 16.7 NT 16.7 NT 0 
Zhou et al. 2017 84 4.8 2.4 2.4 0 0 0 4.8 72.6 100.0 35.2 NT 36.9 0 NT 
Zhao  2017 45 0 NT NT 0 0 2.2 NT 64.4 NT NT NT 42.2 NT NT 
Guan et al. 2018 68 0 NT NT 0 0 0 NT 57.4 95.6 NT NT 5.9 NT NT 
Median NA NA 0 0 21.2 0 0 0 55.8 64.4 98.0 25.0 9.1 17.7 0 0 
IQI 25% NA NA 0 0 0.6 0 0 0 9.8 56.6 80.0 9.1 3.3 6.9 0 0 
IQI 75% NA NA 0 1.7 72.5 60.0 0 0 96.7 75.0 100 35.2 42.8 41.2 0 0 
*Values are percentages. Reference details are provided in the Appendix (https://wwwnc.cdc.gov/EID/26/11/18-1414-App1.pdf). Green indicates a rate of 
AMR <25%; yellow 25%–50%; red >50%; 25%, and 75% refers to AMR interquartile interval of 25% and 75%. Amp, ampicillin; CFZ, cefazolin; CAX, 
ceftriaxone, CHL, chloramphenicol; CIP, ciprofloxacin; ERY, erythromycin; IQI, interquartile interval; LZD, linezolid; MXF, moxifloxacin; NA, not applicable; 












However, GBS isolates were susceptible to penicil-
lin, ampicillin, vancomycin, and linezolid, consistent 
with other reports (9,21,22). The apparent resistance 
to ceftriaxone is unusual and, as noted, the sample 
size for these 2 studies was small. Furthermore, be-
cause no details were provided on the methods used 
for testing the isolates, it is essential that this reported 
resistance is verified.
The serotype and MLST distribution of invasive 
GBS disease isolates in China is consistent with the 
global review (4); serotype III and ST17 are the most 
prevalent types (21,29). Therefore, our data suggest 
that a conjugate vaccine incorporating 5 serotypes 
(III, Ia, Ib, II, and V) could cover 97% of invasive GBS 
disease in infants <3 months of age in China.
Currently, there is limited evidence on the 
burden of GBS disease for infants in China. Our 
comprehensive review is a major addition to the 
literature because it includes a systematic review 
of studies in the Chinese language, as well as data 
on incidence, antimicrobial drug susceptibility, and 
MLST types.
There are several potential limitations to this 
study. First, major heterogeneity among studies was 
observed. Although potential sources of heteroge-
neity were explored by subgroup analyses, none of 
them sufficiently explain the heterogeneity. Sensitiv-
ity analysis suggests that the pooled estimated inci-
dence and CFR was changed when Taiwan, Hong 
Kong, and Macau were excluded. This finding is 
plausible and might reflect the differences in health-
care systems compared with those of mainland Chi-
na. Second, we did not search for unpublished stud-
ies, which could result in publication bias. Third, we 
were not able to assess the time of sample collection 
or the methods of collection, culture, and antimi-
crobial drug sensitivity testing. Fourth, there were 
limited data available on serotypes and MLST types; 
thus, meta-analysis was not possible. Fifth, for CFRs, 
we were only able to include patients who died in a 
hospital; thus, the true CFR might be higher.
The estimated burden of infant GBS disease in 
China is substantial, suggesting that implementation 
of additional prevention efforts could be beneficial. 
Interventions to be considered could include a coor-
dinated national strategy for maternal GBS screen-
ing with administration of intrapartum antimicro-
bial drug prophylaxis, and, when available, maternal 
vaccination with an effective GBS vaccine. Further 
research to clarify the noted heterogeneity in infant 
GBS disease in China, as well as research to assess the 
acceptability, logistics, and cost-effectiveness of ma-
ternal GBS vaccination could help guide these efforts.
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Appendix Table 1. Search terms (for English papers) and search period (January 1, 2000–March 16, 2018) for PubMed/ Medline or 






Case AND Fatality AND rate 
Death [MeSH terms] 
Mortality [MeSH terms] 




Streptococci AND (Group AND B) or agalactiae 




Streptococcus agalactiae serotype [MeSH terms] 
*MeSH, medical subject headings 
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Appendix Table 2. Search terms (for Chinese papers) and search period (January 1, 2000–March 16, 2018) for China National 
Knowledge Infrastructure or Wanfang med online databases (search date: March 18, 2018) 
Search term 
族链 链 链  (Group B Streptococcal) 
无乳链 链 链  (Streptococcus agalactiae) 
AND 
新生儿 (Neonatal) 





Appendix Table 3. Inclusion and exclusion criteria* 
Characteristic Inclusion criteria Exclusion criteria 
Population Invasive GBS disease in infants <1–89 days of age 
at onset of infection 
Studies containing only information on high-risk groups 
Laboratory GBS confirmed by blood, CSF, or other sterile site 
culture 
NA 
Search No language restrictions Foreign language papers for which it was not possible to 
obtain English or Chinese translations 
Study Study reporting more recent data from country or 
hospital 
Case report, case series, reviews, conference papers; 
studies from the same country or hospital reporting 
repeated years or data. 
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Appendix Table 4. Characteristics of included studies for infant invasive group B Streptococcus (GBS) disease in children* 
Reference Region of China 
Year of 
publication Year of data collection Incidence CFR AMR Serotype MLST IAP 
Reporting 
period, y Study design 
Chang CJ et al. (1) Taiwan 2003 1986.1–2001.12 N Y N N N U <1–89 R 
Chung MY et al. (2) Taiwan 2004 1996.1.1–2002.12.31 Y Y N N N U <1–89 R 
Jiang JH et al. (3) Taiwan 2004 1992.1–2001.12 N Y N N N N <1–89 R 
Wu JH et al. (4) Taiwan 2009 2001.1–2006.12 N Y N N N U <1–89 P 
Wang P et al. (5) Beijing 2010 2005–2009 Y Y N N N U <1–6 R 
Liu ZW et al. (6) Shang Hai 2011 1999.1–2008.12 N Y N N N U <1–89 R 
Lin CY et al. (7) Taiwan 2011 2001.1–2008.11 Y N N N N Y <1–6 R 
Yu HW et al. (8) Taiwan 2011 2002.1–2005.6 Y Y N N N Y <1–89 R 
Wu MF (9) Guang Dong 2012 2008.1–2012.1 N Y N N N U <1–89 R 
Dai YH et al. (10) Guang Dong 2012 2008.6–2011.4 Y Y N N N U <1–89 R 
Long YM et al. (11) Guang Dong 2012 2009.7–2011.6 Y Y N N N U <1–89 R 
Zeng SJ et al. (12) Guang Dong 2013 2012.1–2012.12 N Y Y N N U <1–89 R 
Luo J et al. (13) Guang Dong 2013 2007.1–2011.12 N Y Y N N U 7–89 R 
Chen L et al. (14) Guang Dong 2013 2010–2012 N Y N N N U <1–89 R 
Al-Taiar A et al. (15) Macau 2013 2006.1.1–2009.12.31 Y N N N N U <1–89 P 
Wu YY (16) Guang Dong 2014 2010–2013 N Y N N N U <1–89 R 
Fan WH et al. (17) Beijing 2014 2011.1–2013.9 N N Y N N U <1–89 R 
Zheng Z et al. (18) Fujian 2014 2011.10–2013.4 Y Y Y N N Y <1–6 R 
Chen Y et al. (19) Guang Dong 2014 2011.1–2013.10 N Y Y N N U <1–6 R 
Wei CP et al. (20) Shan Dong 2014 2012–2014 N Y N N N U <1–89 R 
Huang HJ et al. (21) Guang Dong 2014 2011.1–2012.12 N Y N N N U <1–89 R 
Long YM et al. (22) Guang Dong 2014 2011.1–2013.12 Y Y N N N U <1–89 R 
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Reference Region of China 
Year of 
publication Year of data collection Incidence CFR AMR Serotype MLST IAP 
Reporting 
period, y Study design 
Zhu ML et al. (23) Zhe Jiang 2014 2005.1–2013.5 N Y Y N N Y <1–89 R 
Liu X et al. (24) Jiang Su 2015 2013.3–2015.3 N Y N N N U <1–89 R 
Zhang S et al. (25) Guang Dong 2015 2013.1–2014.3 N Y Y N N U 7–89 R 
Zeng SJ et al. (26) Guang Dong 2015 2012–2014 N N N Y N U <1–89 R 
Li K et al. (27) Guang Dong 2015 2011.3–2014.2 N Y N N N U <1–89 R 
Wang QQ et al. (28) Zhe Jiang 2015 2010.4–2014.4 Y Y Y N N Y <1–89 R 
Wang YC et al. (29) Jiang Su 2015 2013.1–2013.12 N Y N N N Y <1–89 R 
Luo MJ et al. (30) Guang Dong 2015 2010–2012 N Y N N N U <1–6 R 
Zhao N et al. (31) Guang Dong 2015 2011.11–2014.4 N Y N N N U <1–89 R 
Lei MF et al. (32) Tianjin 2015 2006.12.-2014.09 N Y Y N N U <1–89 R 
Liu H et al. (33) Guang Dong, Hunan 2015 2013.09–2014.09 Y Y N Y Y Y <1–89 P 
Rivera L et al. (34) Hong Kong 2015 U Y Y N N N Y <1–89 P 
Zhang JS et al. (35) Guang Dong 2015 2010–2014 N Y Y N N U <1–89 R 
Liu ZY et al. (36) Fu jian 2016 2011.3–2014.10 N Y N N N U <1–89 R 
Zhang XH et al. (37) Shan Xi (Tai Yuan) 2016 2013.1–2015.11 N Y N N N U <1–89 R 
Li L et al. (38) Guang Dong 2016 2008.1–2014.8 N Y N N N U <1–89 R 
Li YH et al. (39) Nei Menggu 2016 2013.6–2016.6 Y Y N N N U <1–89 R 
Yang HH et al. (40) Shang Hai 2016 2012.1–2015.5 N Y N N N N <1–89 R 
Shen YH et al. (41) Beijing 2016 2008.1–2014.1 N Y N N N U <1–89 R 
Cai YF et al. (42) Guang Dong 2016 2011.1–2014.10 N Y Y N N U <1–89 R 
Lai JD et al. (43) Fu Jian 2016 2010.1–2015.2 N Y N N N U <1–6 R 
Zhao L (44) Jiang Su 2016 2014.4–2016.4 N Y Y N N U <1–89 R 
Ju HQ et al. (45) Shang Hai 2016 2010.3–2015.2 N Y N N N U <1–89 R 
Huang LF et al. (46) Guang Dong 2016 2010.11–2014.2 N N Y N N U <1–89 R 
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Reference Region of China 
Year of 
publication Year of data collection Incidence CFR AMR Serotype MLST IAP 
Reporting 
period, y Study design 
Yue D (47) Hu Bei 2017 2014.1–2016.1 N Y N N N U <1–89 R 
Qiao LY et al. (48) Shan Dong 2017 2012.1–2016.1 N Y N N N U 7–89 R 
Guan XS et al. (49) Guang Dong 2017 2012.1–2015.12 N Y N N N U <1–89 R 
Liu WW et al. (50) Guang Dong 2017 2012.1–2015.12 N Y Y N N U <1–89 R 
Lv CH (51) Shan Dong 2017 2014.1–2015.12 N Y N N N U <1–89 R 
Zhou YZ et al. (52) Zhe Jiang 2017 2008.2–2016.11 N N Y Y N U <1–89 R 
Zhang JS et al. (53) Guang Dong 2017 2010.1.1–2015.21.31 N Y Y N N U <1–89 R 
Zhang N et al. (54) Shan Dong 2017 2013.1–2016.5 N Y Y N N N <1–89 R 
Wang YJ et al. (55) Guang Dong 2017 2011.4–2015.4 N Y N N N U 7–89 R 
Shenzhen GBS study group (56) Guang Dong 2017 2010.1–2016.6 N Y N N N Y <1–89 R 
Zhang S et al. (57) Beijing 2017 2010–2014 N Y N N N U <1–89 R 
Tan KH et al. (58) Guang Dong 2017 2012.3–2016.3 N N Y N N N <1–89 R 
Zhao TL (59) Liaoning 2017 2015.1–2016.2 N N Y N N U <1–89 R 
Ma HL et al. (60) Si Chuan 2017 2014.1–2016.2 N Y N N N U <1–6 R 
Huang W et al. (61) Gong Dong, Guang Xi 2017 2013.1–2015.2 N Y N N N U <1–89 R 
Chen IL et al. (62) Taiwan 2017 2008.1–2013.12 N Y N N N U <1–89 R 
Chen HY et al. (63) Zhe Jiang 2018 2014.6.1–2017.6.31 N Y N N N Y <1–89 R 
Guan XS et al. (64) Guang Dong 2018 2011.1–2014.12 Y Y Y Y Y U <1–89 R 
*AMR, antimicrobial drug resistance; CFR, case-fatality rate; GBS, group B Streptococcus; IAP, intrapartum antimicrobial drug prophylaxis; MLST, multilocus sequence typing; N, no; P, prospective study; R, 
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Appendix Table 5. Studies with reasons for exclusions 
Reference Year of publication Year of data collection Reasons for exclusion 
Resiner DP et al. (65) 2000 1994.2–1997.1 Studies not from China 
Chang C et al. (66) 2000 1984–1997 Investigating only specific clinical manifestations 
Zhong Y et al. (67) 2002 1998.11–1999.7 Not fulfilling inclusion criteria 
Liao CH et al. (68) 2002 1980.1–2000.3 No full text 
Tiskumara R et al. (69) 2009 2005.1.1–2005.12.31 Studies not from China 
Lin MC et al. (70) 2012 1984–2008 Investigating only specific clinical manifestations 
Ye F et al. (71) 2013 2009–2011 Other topics 
Zhang J et al. (72) 2013 2010.1–2011.1 Case report 
Lin Z et al. (73) 2013 2009.1–2013.5 Investigating only specific clinical manifestations 
Tan JF et al. (74) 2014 2011.8–2012.8 Other topics 
Chu SM et al. (75) 2014 20014.1–2011.12 Other topics 
Zhang J et al. (76) 2015 2009.1–2012.12 Duplicate data analysis 
Li L et al. (77) 2015 2008.1–2014.8 Not fulfilling inclusion criteria 
Mu L et al. (78) 2015 2011.7.2014.7 Specimen not obtained from sterile site 
Zhong H et al. (79) 2015 2011–2014 Specimen not obtained from sterile site 
Zhong H et al. (80) 2015 2011.1–2014.5 Duplicate data analysis 
Wang P et al. (81) 2015 2008–2013 Not defined laboratory methods 
Li L et al. (82) 2016 2008.1–2014.8 Not fulfilling inclusion criteria 
Wang Y et al. (83) 2016 2013.9–2015.9 Specimen not obtained from sterile site 
Geng H et al. (84) 2016 2010–2015 Other topics 
Huang J et al. (85) 2016 2011.11–2015.9 Specimen not obtained from sterile site 
Hua CZ et al. (86) 2016 2011.1–2015.12 Investigating only specific clinical manifestations 
Ding Y et al. (87) 2017 2008–2015 Case report 
Wang Y et al. (88) 2017 2015.10–2016.12 Specimen not obtained from sterile site 
Jing L et al. (89) 2017 2009.1–2015.2 Specimen not obtained from sterile site 
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Appendix Table 6. Results of subgroup analysis of total incidence of GBS invasive disease* 
Subgroup No. studies Incidence (95% CI) 
Heterogeneity test 
I2, % Q test p value 
Study design     
 Retrospective 10 0.54 (0.32–0.75) 88.20 0.001 
 Prospective 3 0.60 (0.12–1.08) 56.80 0.10 
Isolate type     
 Blood 5 0.37 (0.14–0.60) 69.70 0.01 
 All sterile sites 1 1.17 (0.89–1.44)   
 Blood plus CSF 7 0.52 (0.35–0.69) 46.00 0.09 
Age of onset, y     
 EOGBS 11 0.38 (0.25–0.51) 65.40 0.001 
 LOGBS 3 0.18 (0.11–0.25) 0.0 0.45 
*CSF, cerebrospinal fluid; EOGBS; early-onset group B Streptococcus; LOGBS, late-onset group B Streptococcus. 
 
 
Appendix Table 7. Relationship between group B Streptococcus serotypes and MLST results* 
Author No samples Serotype ST17 ST12 ST23 ST10 ST1 New 17-like 
Liu H et al. 2 III 1 0 0 0 0 1 
 3 Ib 0 2 0 1 0 0 
 2 Ia 0 0 2 0 0 0 
 1 V 0 0 0 0 1 0 
Guan XS et al. 53 III 43 0 0 0 0 0 
 10 Ib 0 5 1 1 0 0 
 2 Ia 0  2 0 0 0 
 3 V 0 0 0 0 3 0 
*MLST, multilocus sequence typing; ST, sequence type. 
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Appendix Figure 1. Publication year of included studies of infants invasive group B 




Appendix Figure 2. Risk for bias in the studies. Colored circles indicate different risks. Green, 
low risk; yellow, unknown risk; red, high risk.  
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Appendix Figure 3. Incidence risk for early-onset group B Streptococcus (EOGBS) disease (n = 
11). Vertical dashed line indicates a visual assessment of heterogeneity of the studies. If the 
vertical line can be drawn, forest plots indicate that all studies are similar enough to be included 
for meta-analysis. Error bars indicate 95% CI. ES, effect size; GBS, group B Streptococcus 
disease. 
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Appendix Figure 4. Incidence risk for late-onset (age 7–89 days) group B Streptococcus 
(LOGBS) disease (n = 3). Vertical dashed line indicates a visual assessment of heterogeneity of 
the studies. If the vertical line can be drawn, forest plots indicate that all studies are similar 
enough to be included for meta-analysis. Shaded areas indicate relative weight that each 
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Appendix Figure 5. Sensitivity analysis of GBS invasive diseases incidence studies. A) Total 
incidence of GBS invasive disease in Mainland China; B) total incidence of GBS invasive disease 
in Taiwan, Hong Kong, and Macau; C) total CFR of GBS invasive disease in Mainland China; D) 
total CFR of GBS invasive disease in Taiwan, Hong Kong, and Macau. Vertical dashed line 
indicates a visual assessment of heterogeneity of the studies. If the vertical line can be drawn, 
forest plots indicate that all studies are similar enough to be included for meta-analysis. Shaded 
areas indicate relative weight that each individual study contributes to the overall pooled effect. 
ES, effect size; GBS, group B Streptococcus disease.  
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Appendix Figure 6. Funnel plot showing publication bias for group B Streptococcus disease. 
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Appendix Figure 7. Case-fatality rate of group B Streptococcus (GBS) disease in infants <1–89 
days of age (n = 56). Vertical dashed line indicates a visual assessment of heterogeneity of the 
studies. If the vertical line can be drawn, forest plots indicate that all studies are similar enough to 
be included for meta-analysis. Shaded areas indicate relative weight that each individual study 
contributes to the overall pooled effect. CFR, case-fatality rate; ES, effect size; GBS, group B 
Streptococcus disease.  
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Appendix Figure 8. Case-fatality rate (CFR) of early-onset group B Streptococcus (EOGBS) 
disease (n = 38). Vertical dashed line indicates a visual assessment of heterogeneity of the 
studies. If the vertical line can be drawn, forest plots indicate that all studies are similar enough to 
be included for meta-analysis. Shaded areas indicate relative weight that each individual study 
contributes to the overall pooled effect. EOD, patient died in the hospital; ES, effect size.  
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Appendix Figure 9. Case fatality rate (CFR) of late-onset group B Streptococcus (LOGBS) 
disease in children 7–89 days of age (n = 37). Vertical dashed line indicates a visual assessment 
of heterogeneity of the studies. If the vertical line can be drawn, forest plots indicate that all 
studies are similar enough to be included for meta-analysis. Shaded areas indicate relative 
weight that each individual study contributes to the overall pooled effect. LOD, patient died in the 
hospital; ES, effect size.  
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Appendix Figure 10. Serotype distribution of group B Streptococcus (GBS) in infants <1–89 
days of age with invasive disease. A) Overall serotype distribution of GBS; B) distribution of early-
onset GBS disease; C) distribution of late-onset GBS disease. EOGBS, early-onset GBS disease; 
LOGBS, late-onset GBS disease. 
